COMMUNIQUÉS West-GlobeNewswire

Curia Appoints Steve Lavezoli as Vice President, Biologics
23/02/2024
ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective [...]
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
23/02/2024
EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
23/02/2024
Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29 th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or [...]
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
23/02/2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months [...]
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
23/02/2024
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
23/02/2024
TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive [...]
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23/02/2024
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing [...]
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
23/02/2024
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel-onlv) Preliminary [...]
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
23/02/2024
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small- [...]
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
23/02/2024
Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, [...]
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
23/02/2024
For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND [...]
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
23/02/2024
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is [...]
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
23/02/2024
SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new [...]
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
23/02/2024
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO ® (berotralstat) that showed [...]
Castellum, Inc. Announces Closing of $4 Million Revolver with Live Oak Bank
23/02/2024
BETHESDA, Md., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity and software services company focused on the federal government, announces that it has closed its previously [...]
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
23/02/2024
Results from the Phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment 1 Most patients with [...]
Aino Health year-end report January-December 2023
23/02/2024
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Implemented 100,000 licences. Solid growth according to plan. Improved profitability [...]
Mendus to hold Business Update event on March 12
23/02/2024
Press Release Stockholm, Sweden, February 23, 2024 Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company’s [...]
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
23/02/2024
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms [...]

Pages